To assess the association of CD8+ T cells, Mφ, and PD-L1 expression and response to tislelizumab, an mIHC panel was developed including CD8 (cytotoxic T cells), CD68 (tumor-associated Mφ), CD64, PD-L1, and Pan-cytokeratin (tumor cell) surface markers to identify cell subtypes in the TME (Supplemental Fig. 1A). The gene discussed is CD8A; the disease is neoplasm.